Non-small-cell lung cancer

Gridelli, Cesare; Rossi, Antonio; Carbone, David P.; Guarize, Juliana; Karachaliou, Niki; Mok, Tony; Petrella, Francesco; Spaggiari, Lorenzo; Rosell, Rafael

doi:10.1038/nrdp.2015.9

Cited by 794 publications

(662 citation statements)

References 156 publications

Supporting

Mentioning

621

Contrasting

Unclassified

Order By: Relevance

“…[1,2] Nonsmall-cell lung cancer (NSCLC), which accounts for approximately 85% primary lung cancers, consists of adenocarcinoma, squamous cell carcinoma, large cell carcinoma, sarcomatoid carcinoma, and adenosquamous cell carcinoma. [3,4] Meanwhile, adenocarcinoma, the main subtype of NSCLC, is the most aggressive histological type in lung cancer.…”

Section: Introductionmentioning

confidence: 99%

High expression of CD8 predicts favorable prognosis in patients with lung adenocarcinoma

Li²,

Zhao³

et al. 2017

Medicine

View full text Add to dashboard Cite

Lung carcinoma is the most common cause of malignant death worldwide. CD8+ T cells, as critical elements in antitumor immunity, could function as good prognostic indicators in various kinds of cancers such as renal cell carcinoma and colorectal cancer, but its prognostic role in lung adenocarcinoma is still unclear. The objective of this study was to explore the prognostic role of CD8 expression in lung adenocarcinoma.Paired tumor and adjacent noncancerous tissues were obtained from 102 patients with lung adenocarcinoma, and CD8 expression of these samples was examined by immunohistochemistry. We evaluated the relationships between the expression of CD8 and pathological grade, TNM stage, clinical stage, as well as overall survival (OS).Expression of CD8 was significantly increased in lung adenocarcinoma compared with that in adjacent lung adenocarcinoma (P < .001). CD8 expression was negatively correlated with pathological grade (r = –0.216, P = .022) and N stage (r = –0.372, P < .001), while no statistical correlation with T stage, or clinical stage. Importantly, OS was numerically increased in patients with high expression of CD8 than the group of intermediate and low CD8 expression (P = .12). Furthermore, CD8 could significantly increase OS (P = .043, HR: .713, 95%CI: .515–.989) by univariate Cox's proportional hazards regression analysis.Our data indicated that expression of CD8, as a protective factor, is correlated with the outcome of patients with lung adenocarcinoma. Furthermore, CD8 might be a novel prognostic biological marker for patients with lung adenocarcinoma.

show abstract

Section: Introductionmentioning

confidence: 99%

High expression of CD8 predicts favorable prognosis in patients with lung adenocarcinoma

Li²,

Zhao³

et al. 2017

Medicine

View full text Add to dashboard Cite

show abstract

“…); Tumor volumes and animal weights were recorded weekly. Tumor volumes were estimated using the equation of 0.5 × length × (width) 2 . All animals were observed daily to assess general health.…”

Section: Tumor Xenografts and Treatment Designmentioning

confidence: 99%

“…Non-small-cell lung cancer (NSCLC), the mostly common cancer subtype, accounts for 85% of all new lung cancer diagnoses [2]. Due to late onset of clinical manifestations, patients are commonly diagnosed at advanced or inoperable-stages.…”

Section: Introductionmentioning

confidence: 99%

Re-188 Enhances the Inhibitory Effect of Bevacizumab in Non-Small-Cell Lung Cancer

Xiao

et al. 2016

Molecules

View full text Add to dashboard Cite

Abstract:The malignant behaviors of solid tumors such as growth, infiltration and metastasis are mainly nourished by tumor neovascularization. Thus, anti-angiogenic therapy is key to controlling tumor progression. Bevacizumab, a humanized anti-vascular endothelial growth factor (VEGF) antibody, plus chemotherapy or biological therapy can prolong survival for cancer patients, but treatment-related mortality is a concern. To improve inhibitory effect and decrease side-effects on non-small-cell lung cancer (NSCLC), we used Re-188, which is a β emitting radionuclide, directly labeled with bevacizumab for radioimmunotherapy in a human A549 tumor model. Cytotoxic assay data showed that, after 188 ReO 4 − or 188 Re-bevacizumab at different concentration for 4 and 24 h, a time-and radioactivity does-dependent reduction in cell viability occurred. Also, an apoptosis assay conformed great apoptosis in the 188 Re-bevacizumab group compared with controls and other treatment groups. In vivo, tumor volumes in the 188 Re-bevacizumab (11.1 MBq/mice) group were not reduced but growth was delayed compared with other groups. Thus, 188 Re-bevacizumab enhanced the therapeutic effect of bevacizumab, suggesting a potential therapeutic strategy for NSCLC treatment.

show abstract

“…Chronic obstructive pulmonary disease (COPD) and lung cancer remain major public concerns due to the increased morbidity and mortality with which they are globally associated (1,2). COPD is a risk factor for lung cancer, and studies into associations between COPD and lung cancer have suggested strategies for decreasing the burden of the conditions (3).…”

Section: Introductionmentioning

confidence: 99%

Function of macrophage scavenger receptor 1 gene polymorphisms in chronic obstructive pulmonary disease with and without lung cancer in China

et al. 2018

View full text Add to dashboard Cite

Non-small-cell lung cancer

Cited by 794 publications

References 156 publications

High expression of CD8 predicts favorable prognosis in patients with lung adenocarcinoma

High expression of CD8 predicts favorable prognosis in patients with lung adenocarcinoma

Re-188 Enhances the Inhibitory Effect of Bevacizumab in Non-Small-Cell Lung Cancer

Function of macrophage scavenger receptor 1 gene polymorphisms in chronic obstructive pulmonary disease with and without lung cancer in China

Contact Info

Product

Resources

About